Biomaterials
Regentis Biomaterials Advances Cell-Free Knee Cartilage Implant, Targeting Major Market Gap
Regentis Biomaterials is advancing GelrinC, a ready-to-use hydrogel implant for knee cartilage repair, addressing a U.S. market of approximately 470,000 annual cases lacking an approved off-the-shelf regenerative solution.
Regentis Biomaterials Advances Toward Key Milestones for Simplified Cartilage Repair Platform
Regentis Biomaterials Ltd. is progressing its GelrinC hydrogel implant toward European commercialization and U.S. FDA submission, targeting a $3 billion market for knee cartilage repair with a cell-free, single-step procedure.
Regentis Biomaterials Targets $3 Billion Knee Cartilage Repair Market with Off-the-Shelf GelrinC Platform
Regentis Biomaterials’ GelrinC platform shows promise as a first-in-class, off-the-shelf solution for knee cartilage repair, with clinical data indicating approximately 100% greater pain improvement versus microfracture and a clear path to U.S. market entry.
Regentis Biomaterials Targets Major Gap in Knee Cartilage Repair with Off-the-Shelf Implant
Regentis Biomaterials Ltd. is advancing GelrinC, a cell-free hydrogel implant for knee cartilage repair, which could address a significant unmet need in the U.S. market where no off-the-shelf regenerative solution currently exists.
Regentis Biomaterials Targets Knee Cartilage Repair Market with Off-the-Shelf Hydrogel Implant
Regentis Biomaterials advances GelrinC, a cell-free hydrogel implant for knee cartilage repair, as clinical trials progress and a new manufacturing process scales production.